Market Insights

Whitepaper9 min read

M&A and Private Equity Activity Within the Rheumatology Sector

A Guide for Independent Practice Owners on Valuation, Buyers, and Strategic Timing

Rheumatology Practice M&A: What Practice Owners Need to Know

Rheumatology practice acquisitions are accelerating – and the window for independent practice owners to maximize value is open now.

Rheumatology has become one of the most strategically important segments in healthcare services. Rising rates of chronic inflammatory disease, a rapidly aging patient population, and the widespread adoption of high-cost biologic therapies have transformed a fragmented specialty into an active target for health systems, group purchasing organizations, and institutional investors.

The sector’s appeal is structural. Rheumatology practices generate recurring, high-value revenue through long-term patient relationships and in-office infusion services – an economic profile that is both predictable and scalable. At the same time, the independent practice landscape remains largely unconsolidated, presenting a meaningful opportunity for well-capitalized buyers.

For practice owners evaluating their options – whether a near-term transaction or a process years away – understanding the buyer landscape and the drivers of value is essential. The practices that achieve the strongest outcomes enter a process prepared: clean financials, a differentiated clinical story, and clarity on what they want from a partner beyond the headline price.

Rheumatology Market Outlook: Why Buyers Are Moving Now

The rheumatology therapeutics market is projected to grow from $83.34 billion in 2024 to $108.76 billion by 2029 – a compound annual growth rate of 5.2%. That growth is structural, not speculative. (GlobalData, 2024)

Three forces are driving it. First, the prevalence of rheumatic and autoimmune conditions continues to rise with an aging population – approximately 54 million Americans live with some form of arthritis, and inflammatory conditions including rheumatoid arthritis, lupus, and psoriatic arthritis affect tens of millions more. Second, the transformation of treatment through biologics and oral JAK inhibitors has changed what disease management looks like and who delivers it. These therapies require specialist oversight, careful monitoring, and in many cases in-office administration. Third, patients are living longer with chronic disease, increasing the lifetime treatment demand per patient.

The economic profile of rheumatology is as distinctive as its clinical one. Unlike many specialties where revenue is episodic, rheumatology practices generate recurring revenue through long-term patient relationships. Infusion services compound that stability, converting each treatment cycle into predictable, high-value clinical and technical revenue. This combination – chronic disease management plus high-cost biologic administration – creates a practice model that sophisticated partners actively seek to support and grow.

Rheumatology M&A Deal Activity: Early Consolidation Cycle

Private equity and strategic acquirers have been active in physician practice M&A for more than a decade, but not all specialties have seen equal attention. Rheumatology has historically attracted fewer transactions than dermatology, gastroenterology, or cardiology – and that is precisely what makes it compelling for practice owners evaluating their options today.

Early-cycle consolidation means the market is building, not saturated. Platforms are actively seeking anchor practices – well-run, multi-physician groups that will form the foundation of a regional or national network. Anchor practices command materially higher valuations than add-on acquisitions, and practices that move in the next two to four years are likely to capture that premium.

Chart of rheumatology physician-specialty consolidation stage

Notable Rheumatology Transactions

While deal volume has been modest compared to other specialties, the transactions that have occurred signal growing institutional interest:

The pattern is clear: buyers are most interested in practices with scale, diverse service lines, and data infrastructure. The early transactions are establishing what an ideal rheumatology platform looks like – and practices that resemble that profile will be most sought after. Private equity is treating rheumatology as a platform-building opportunity – not a one-off bet.

Infusion Therapy in Rheumatology: The Highest-Value Revenue Line

The most consequential value driver in rheumatology is in-office infusion. Specialty infusion – biologics and other high-cost therapies administered for chronic inflammatory conditions – generates per-patient revenue substantially higher than a standard office visit, while deepening the patient relationship and extending treatment continuity.

The infusion services market exceeds $100 billion and is projected to grow at 8.6% annually, driven by a shift in care from inpatient settings to lower-cost ambulatory and in-office environments. (Grand View Research / MHA analysis) Deal volume in infusion reached its highest level on record in 2024, with 11 new platform transactions announced – more than 2022 and 2023 combined. Much of the capital touching rheumatology patients is flowing through infusion center acquisitions, meaning practices with established infusion programs simultaneously attract practice-focused buyers and infusion-platform partners.

Recent Infusion Transactions

Practices without infusion programs should not see this as a disqualifier. A well-run practice that has not yet built an infusion program may find that a partner’s capital and operational support accelerates exactly that development – creating better care options for patients and long-term growth for the practice.

What a Private Equity or Strategic Partner Brings to Your Rheumatology Practice

The question most practice owners ask is a reasonable one: what exactly does a partner bring to a practice I have built over years? When the right partner is involved, the answer goes well beyond capital. The best partnerships allow physicians to do more of what they trained to do, by removing the operational, administrative, and financial constraints that consume time and limit growth.

Business Management and Administrative Relief

Revenue cycle management, payer contract negotiations, billing compliance, human resources, credentialing, malpractice, IT infrastructure – none of this is clinical work, and all of it takes physician time and energy. Strategic partners with established management services organizations absorb these functions, often reducing administrative overhead and improving collection rates simultaneously.

Physician and APP Recruitment

Finding, recruiting, and onboarding new physicians and advanced practice providers takes resources that most independent practices lack. Strategic partners with institutional backing offer a fundamentally different recruiting profile – competitive compensation structures, partnership tracks, and professional development opportunities that attract younger rheumatologists weighing their options.

Capital for Growth and New Service Lines

Independent practices grow through capital: building infusion suites, opening satellite locations, hiring physicians, expanding into clinical research, diagnostic services, and telehealth. A well-structured partnership provides access to capital on terms aligned with the practice’s growth trajectory – enabling practices to serve patients who currently have nowhere to go.

Rheumatology Practice Valuation: EBITDA Multiples and Key Value Drivers

Practice valuations in specialty M&A are expressed as a multiple of EBITDA – a measure of normalized operating earnings. For rheumatology practices, multiples reflect both the strength of the specialty’s fundamentals and the early-cycle nature of consolidation.

Two factors have the greatest influence on where a practice lands: size (EBITDA scale) and service line composition – particularly the presence of infusion revenue and other ancillaries. Commercial payer mix is a primary driver; practices with strong commercial revenue consistently achieve higher multiples than those concentrated in government payers.

For reference, comparable specialty multiples in mid-cycle consolidation range from 9x-13x for orthopedics platforms and 10x-14x for GI platforms. As rheumatology consolidation matures and established platforms compete for remaining independent groups, multiple expansion is a reasonable expectation – particularly for practices with strong infusion economics and multi-physician scale.

“The quality of process management – including preparation, buyer targeting, and competitive tension – can account for 2x to 4x turns of multiple difference between a well-run process and an unprepared one.”

Several variables have the greatest leverage on final valuation. Commercial payer mix is a primary driver – practices with higher commercial exposure and lower Medicare/Medicaid concentration typically achieve higher multiples. An active infusion program can add 1.5x to 3.0x to enterprise value. And the quality of process management – including preparation, buyer targeting, and competitive tension – can account for 2x to 4x turns of multiple difference between a well-run process and an unprepared one.

Why Work With a Healthcare M&A Advisor for Your Rheumatology Sale?

For an independent rheumatology practice, the difference between an adequate transaction and an exceptional one often comes down to preparation and representation. Merritt Healthcare brings over two decades of healthcare transaction experience and a track record that includes major health system partnerships – the kind of institutional credibility that signals to buyers that a process will be run with discipline.

What Merritt Delivers

  • Preparation of a detailed Confidential Information Memorandum (CIM) presenting the practice’s clinical model, growth trajectory, and financial profile in the most compelling, accurate terms.
  • Proactive outreach to a curated universe of qualified buyers – PE platforms, strategic acquirers, health systems, and infusion-focused partners.
  • Management of due diligence to protect physician time and minimize disruption to daily operations.
  • Negotiation of both economic and non-economic terms: valuation, structure, governance rights, employment agreements, call coverage, and post-close autonomy provisions.
  • Guidance on transaction structure, valuation, tax considerations, and equity rollover options that affect long-term financial outcomes.

Timing and Preparation

Practices that begin preparing 12 to 24 months before a planned transaction consistently achieve better outcomes. Even practices years from a transaction benefit from early advisory engagement – understanding your options and your likely valuation range allows you to make operational decisions with that context in mind.

About Merritt Healthcare Advisors

Merritt Healthcare Advisors is a national healthcare-focused M&A advisory firm representing physician owners, practice groups, ambulatory surgery centers, surgical hospitals, and specialty healthcare organizations in sell-side and buy-side transactions. Merritt advises clients on engagements with private equity platforms, strategic acquirers, value-based care enablers, and health systems.

The firm has deep sector expertise across orthopedics and musculoskeletal care, oncology, cardiology, gastroenterology, ophthalmology, behavioral health, dental, urology, dermatology, and other specialty service lines. With a physician-first approach and a track record of preserving clinical autonomy through transactions, Merritt’s senior bankers are involved in every engagement from origination through closing.

Sources & References

  • GlobalData, rheumatology therapeutics market forecast (2024).
  • Grand View Research; MHA analysis, U.S. infusion services market sizing and growth projections.
  • PESP Healthcare Acquisitions Report; Fierce Healthcare; Becker’s; Irving Levin Associates; MHA analysis – physician specialty consolidation stage and deal volume.
  • VSS Capital Partners / Center for Rheumatology transaction disclosures (2022).
  • Specialty Networks / United Rheumatology and Cardinal Health acquisition disclosures (2022).
  • Audax Private Equity / Corrona (CorEvitas) transaction disclosures (2019).
  • Vivo Infusion / Infusion Associates, InTandem Capital Partners transaction disclosures (July 2024).
  • New Harbor Capital / Access Infusion Care transaction disclosures (January 2024).

All market data and estimates are based on publicly available sources and MHA research; actual transaction outcomes vary.

Start the conversation with Merritt Healthcare Advisors

Thinking about selling your healthcare business? Our team is ready to talk through your options.

Related Content

View all

Schedule Your Appointment Today

Gain insights from the healthcare industry’s leading M&A experts

Merritt Healthcare Advisors (“MHA”) is focused exclusively on representing owners of middle-market healthcare businesses considering strategic options, whether selling an interest in their organization, creating a new partnership or growing through acquisition.